Table 2. Clinical characteristics associated with the 9β polymorphism in healthy controls and AD patients.
| Clinical characteristics | Homozygous G/G genotype | Heterozygous G/A genotype | Wild Type A/A genotype | Controls | Patients | Interaction1 |
| Group N (%) | 0.581 | |||||
| Controls | 5 (0.03) | 36 (0.25) | 105 (0.72) | |||
| Patients | 2 (0.01) | 37 (0.27) | 100 (0.72) | |||
| BMI (IQR) kg/m2 | 0.617 | 0.674 | 0.805 | |||
| Controls | 30.7 (27.4–31.5) | 27.4 (23.7–32.0) | 26.3 (24.1–31.1) | |||
| Patients | 28.2 (27.1–29.3) | 24.1 (22.7–29.0) | 24.8 (22.0–30.2) | |||
| Hypertension Patients | 0 (0.00) | 8 (0.38) | 13 (0.62) | 0.165 | ||
| Diabetes Patients | (0.00) | 7 (0.41) | 10 (0.59) | 0.259 | ||
| Triglycerides (IQR) mmol/L | 0.323 | 0.499 | 0.412 | |||
| Controls | 1.12 (1.12–1.37) | 1.67 (0.93–2.22) | 1.32 (0.98–1.89) | |||
| Patients | 2.77 (1.89–3.64)) | 1.82 (1.29–2.71) | 1.65 (1.10–2.56) | |||
| Total cholesterol (SD) mmol/L | 0.369 | 0.754 | 0.290 | |||
| Controls | 6.80 (1.84) | 5.89 (1.22) | 5.67 (1.24) | |||
| Patients | 5.43 (3.40) | 5.83 (1.28) | 5.74 (1.59) | |||
| HDLC (IQR) mmol/L | 0.978 | 0.716 | 0.193 | |||
| Controls | 1.16 (1.10–1.25) | 1.05 (0.91–1.22) | 1.09 (0.93–1.27) | |||
| Patients | 0.77 (0.77–0.77) | 0.88 (0.70–1.17) | 0.77 (0.44–0.99) | |||
| LDLC (IQR) mmol/L | 0.035 | 0.078 | 0.020 | |||
| Controls | 4.75 (3.68–6.23) | 3.70 (3.30–4.18) | 3.60 (3.15–4.35) | |||
| Patients | 1.79 (1.79–1.79) | 3.73 (2.95–4.68) | 4.28 (3.02–5.04) | |||
| Small dense LDL | 0.336 | 0.701 | 0.510 | |||
| Controls | 0 (0.00) | 0 (0.00) | 5 (1.00) | |||
| Patients | 1 (0.06) | 3 (0.18) | 13 (0.76) | |||
| NEFA (IQR) µmol/L | 0.740 | 0.704 | 0.689 | |||
| Controls | 447.5 (437.0–609.2) | 486.0 (298.5–674.5) | 463.0 (328.0–639.8) | |||
| Patients | 633.0 (582.5–683.5) | 417.0 (192.0–635.0) | 230.0 (126.2–627.2) | |||
| Lipid-lowering therapy | 0.290 | |||||
| Patients | 0 (0.0) | 7 (0.37) | 12 (0.63) | |||
| hs-CRP (IQR) mg/L | 0.743 | 0.485 | 0.769 | |||
| Controls | 0.89 (0.42–6.3) | 1.55 (0.61–3.85) | 1.50 (0.71–2.68) | |||
| Patients | 7.50 (6.90–8.10) | 2.25 (0.87–8.70) | 2.10 (1.05–5.00) | |||
| Hydrocortisone daily dose (IQR) mg | 0.296 | |||||
| Patients | 13.75 (13.12–14.38) | 30.00 (20.00–30.00) | 20.00 (20.00–30.00) | |||
| Framingham risk (IQR) | 0.280 | |||||
| Patients | 29.00 (29.00–29.00) | 13.50 (5.195–21.64) | 13.30 (6.50–25.70) | |||
| TSH (IQR) mIU/L | 0.543 | |||||
| Patients | 2.76 (2.30–3.22) | 1.60 (0.53–1.87) | 1.26 (0.83–2.16) |
N: number, NEFA: non-esterified fatty acids, IQR: interquartile range, SD: standard deviation,
1
comparison between patients and controls-interaction, Significant at the 5% level.